ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019
Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients With Candidemia: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Pooled it
- Healthcare Utilization and Impact of Antifungal Stewardships Within Respiratory Care Settings: A Systematic Literature Review.Mycopathologia · 2021Pooled it
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Sequential Time to Positivity as a Prognostic Indicator in Persistent Candidemia.Open forum infectious diseases · 2026Article
- Persistent candidemia matters: risk factors and clinical outcomes in a retrospective matched cohort study.Infection · 2026Article
- Evaluation of Quantitative Differences of Classic Methods, Fungal Biomarkers, and T2Candida for Assessing the Central Venous Catheter Origin of Candidemia.Open forum infectious diseases · 2026Article
- Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistantAntimicrobial agents and chemotherapy · 2025Observational
- Epidemiological Characteristics and Mortality Predictors of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2025Article
- Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy.Intensive care medicine · 2025Review
- Nine-Year Surveillance ofJournal of fungi (Basel, Switzerland) · 2025Article
- Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study.Infectious diseases and therapy · 2025Article
- Screening, prevalence, and risk factors for secondary localization during candidemia in intensive care unit patients: the French CandidICU multicenter study.Critical care (London, England) · 2025Article
- Trends in Candidemia Over the Last 14 Years: A Comparative Analysis ofOpen forum infectious diseases · 2025Article
- Fluconazole step-down therapy versus echinocandins for the treatment of Candida glabrata invasive candidiasis with candidaemia.The Journal of antimicrobial chemotherapy · 2025Article
- Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.Journal of the Pediatric Infectious Diseases Society · 2023Article
- Epidemiology, antifungal susceptibility, risk factors, and mortality of persistent candidemia in adult patients in China: a 6-year multicenter retrospective study.BMC infectious diseases · 2023Article
- Short Course of Antifungal Therapy in Patients With UncomplicatedOpen forum infectious diseases · 2023Article
- Recurrent Candidemia: Trends and Risk Factors Among Persons Residing in 4 US States, 2011-2018.Open forum infectious diseases · 2022Article
- Clinical and Microbiological Characteristics of Neonates with Candidemia and Impacts of Therapeutic Strategies on the Outcomes.Journal of fungi (Basel, Switzerland) · 2022Article
- Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission.Journal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To investigate the causes and the clinical significance of persistent candidemia (PC) in adults diagnosed in a tertiary hospital with an active antifungal stewardship program. Retrospective cohort including all adults with candidemia from 2010 to 2018. PC was defined as any positive follow-up blood culture (BC) obtained ≥ 5 days from the first BCs yielding the same Candida species. PC was detected in 35/255 (13.7%) patients. There were no differences regarding antifungal adequacy in PC vs. non-PC (94.3% vs. 82.3%, p = 0.084) and primary source control (63.3% vs. 76.4%, p = 0.172) at the time of the follow-up BCs. The average time until source control (2 [0-37] vs. 2 days [0-44], p = 0.311) or adequate antifungal treatment (2 [0-26] vs. 2 days [- 2-10], p = 0.748) was similar. Patients with PC had more non-ocular complications (31.4% vs. 10.5%, p = 0.002). No impact on 30-day mortality was observed (31.4% vs. 22.3%, p = 0.238). The only independent factor associated with PC was to have a previously undetected site of infection [OR 4.28, 95%CI (1.77-10.34), p = 0.001]. Persistent candidemia was not associated with inadequate or delayed therapeutic management, nor higher 30-day mortality rates. Timely screening and control of unexpected infection sources are encouraged to shorten hospitalization and improve patient care.
Indexed as
Identifiers
30680572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.